One of the first questions people ask when they start IVF is also one of the hardest to answer: how many cycles will it take? Clinics, registries and guidelines describe results in different ways, and the numbers can look confusing, or even contradictory, until you know what each one is measuring. This article explains the difference between per-cycle and cumulative outcomes, what large studies and current guidance say about repeating treatment, and which factors shape planning for an individual. It is general education, not a prediction for any one person.
Per-cycle, per-transfer and cumulative: three different questions
Most published IVF figures answer one of three questions, and mixing them up is the commonest source of misunderstanding.
Per embryo transfer: of all embryo transfers performed, what proportion led to a live birth? This is the figure many national registries report. For example, the UK regulator reported a live birth rate of 38% per embryo transferred for patients under 35 and 30% on average across all ages for treatment in 2024 (report published in 2026).
Per started cycle: of all women who began a stimulation cycle, what proportion had a live birth from it? This is lower than the per-transfer figure because some cycles end before a transfer, for example when few eggs are collected or no embryo develops.
Cumulative: of all women who began treatment, what proportion had a live birth after one cycle, then after two, three or more, counting the embryos that were frozen and used later? This is the figure that best answers "how many cycles might I need?"
Researchers also use the term "complete cycle", meaning one round of ovarian stimulation together with every fresh and frozen embryo transfer that comes from it. Because frozen embryos are now widely used, a single stimulation can produce more than one chance of pregnancy, so counting only the first transfer understates what one egg collection may offer.
What large studies show about repeating IVF
Two large analyses of UK national data are widely cited. They are useful for understanding the shape of the curve, although they describe treatment from earlier years and should not be read as current success rates.
A study published in JAMA in 2015 followed 156,947 women across 257,398 IVF cycles. The live birth rate in the first cycle was 29.5% across all women, and it stayed above 20% through the fourth cycle. Using a modelled, prognosis-adjusted estimate, the cumulative live birth rate reached 65.3% by the sixth cycle. For women younger than 40 using their own eggs, the first-cycle figure was 32.3% and the modelled cumulative figure after six cycles was 68.4%. For women aged 40 to 42, the first-cycle figure was 12.3% and the modelled cumulative figure after six cycles was 31.5%. For women older than 42, every within-cycle live birth rate was below 4%. The authors concluded that the results support continuing beyond three or four cycles for women who are able and willing to do so.
A second study, published in Human Reproduction in 2016, analysed records for 178,898 women who started IVF at UK clinics. It reported two cumulative figures because some women stop treatment and their eventual outcome is unknown. The "conservative" estimate assumes that women who stopped would not have had a live birth with further treatment; the "optimal" estimate assumes they would have had the same chance as women who continued. For treatment started between 1999 and 2007, the conservative cumulative live birth rate after three complete cycles was 42.3% and the optimal rate was 57.1%. The optimal rate after eight complete cycles was 82.4%. The true figure for any group lies somewhere between the two estimates.
Three points follow from these studies. First, the chance of a live birth is spread across several attempts, so a single unsuccessful cycle does not mean treatment has failed in general. Second, each additional cycle adds progressively less than the one before it, because women who conceive early leave the group, and those who remain tend to have more difficult underlying problems. Third, age changes the curve dramatically. The numbers above are population averages, and they hide wide variation between individuals.
Why these figures cannot be applied directly to you
Cumulative estimates have important limits. Many of the underlying cycles took place before current laboratory methods, embryo culture and freezing techniques were in routine use, and practice has changed since then. Registry data also combine very different patients: someone with blocked fallopian tubes and normal egg reserve has a very different outlook from someone with severely reduced ovarian reserve or a significant sperm problem. Finally, cumulative figures usually depend on assumptions about the patients who dropped out, which is why ranges are reported.
A practical way to use the numbers is as a map of how outcomes tend to unfold, then ask your own doctor how your age, diagnosis and results so far change the picture.
What guidance says about the number of cycles
Official guidance does not say how many cycles a person needs. It addresses how many cycles public funding should cover, which is a related but different question. NICE guideline NG257, updated in 2026 for England and Wales, advises that people under 40 who meet the eligibility criteria should be offered three full cycles of IVF, and that up to three further full cycles should be considered if those do not result in conception. For people aged 40 or 41 who have not previously had IVF, one full cycle should be offered. Treatment is offered to people who have not yet reached their 42nd birthday, and anyone who turns 40 partway through is advised to complete the current cycle but is not offered more. Eligibility depends on a diagnosed cause of infertility for which other treatments are unsuitable or unsuccessful, or on not having conceived after a defined period of trying or after a series of inseminations.
These recommendations are about access in a publicly funded system. They reflect cost-effectiveness and age-related trends in the evidence. They are not a rule that a particular number of cycles is "enough" or "too many" for an individual, and funding rules in other countries and in private care differ.
Factors that shape how many cycles may be reasonable
Age
Age is the strongest single factor. The American Society for Reproductive Medicine states that age is a much stronger predictor of reproductive success than ovarian reserve. Egg numbers fall with age, and a higher proportion of the remaining eggs have chromosomal abnormalities, which affects both the chance of implantation and the risk of miscarriage. Younger patients tend to have more embryos per cycle and a higher proportion that are chromosomally normal, so they usually move up the cumulative curve faster.
Ovarian reserve and response to stimulation
Blood tests such as anti-Müllerian hormone (AMH) and the ultrasound count of small follicles help predict how many eggs a stimulation is likely to produce. ASRM notes that these markers are good predictors of egg yield but poor predictors of reproductive potential independent of age, and that they should not be the sole reason to deny a person access to treatment. A low result suggests that more than one stimulation may be needed to build up enough embryos, but it does not by itself mean treatment cannot work.
Diagnosis
The underlying cause matters. Blocked tubes, ovulation problems, mild male factor or unexplained infertility often carry a different outlook from advanced maternal age, severe sperm abnormalities, or uterine problems that affect implantation. Identifying and addressing a treatable cause, where one exists, can matter more than simply repeating the same cycle.
What happened in earlier cycles
How many eggs were collected, how many fertilised, how many reached the blastocyst stage and whether any embryos are in storage are all informative. A cycle that produced good-quality embryos but no pregnancy leads to a different conversation than a cycle that was cancelled for poor response. NICE advises that cancellations due to low ovarian response should be considered when deciding whether further IVF is suitable.
Reviewing the plan after each cycle
Rather than committing to a fixed number in advance, many clinicians suggest a structured review after each completed cycle. A useful review usually covers:
How the ovaries responded and whether the stimulation protocol could be adjusted.
How eggs and sperm performed in the laboratory, including whether a different fertilisation method might be appropriate.
The number and quality of embryos created and how many remain frozen.
Whether the uterine lining or cavity should be re-examined if embryos of good quality have not implanted.
Whether other options, such as using donated eggs or sperm, deserve discussion.
Some add-on tests and treatments are marketed to people who have had an unsuccessful cycle. Evidence for many of them is limited. For example, ASRM concluded in 2024 that the value of preimplantation genetic testing for aneuploidy (PGT-A) as a universal screening test for all IVF patients has not been demonstrated, and a Cochrane review it cites found insufficient good-quality evidence of a difference in cumulative live birth rate with and without testing. ASRM does suggest PGT-A may have a role for some older patients, especially those with good ovarian reserve. It is reasonable to ask any clinic recommending an additional test what evidence supports it for your situation.
Single embryo transfer and cumulative planning
Transferring one embryo at a time does not reduce the cumulative chance of a baby, provided additional embryos can be frozen and used in later transfers. It does reduce the chance of twins and higher-order pregnancies, which carry more risk for both mother and babies. In the UK, 84% of embryo transfers in 2024 were single embryo transfers, and the average IVF multiple birth rate fell to 3.2%, from 14.4% in 2014. This shift is part of why cumulative counting, which includes the frozen embryos from each stimulation, is more informative than judging a cycle by its first transfer alone.
Beyond the medical numbers
The question of how many cycles to consider is not only statistical. Cost, time away from work, physical burden and emotional strain accumulate with each attempt, and these vary greatly between families. WHO notes that assisted reproduction remains unaffordable or inaccessible in many parts of the world, so practical limits are often set by resources rather than by medicine. Some people decide at the outset to plan for a set number of cycles, and then reassess. Others prefer to decide after each result. Neither approach is right for everyone, and counselling support can help with the stress of repeated treatment and with deciding when to stop or change direction.
Questions to ask your fertility team
Which figure are you quoting: per transfer, per started cycle or cumulative, and for which age group?
How do my age, test results and diagnosis change the expected pattern compared with the averages?
If this cycle is unsuccessful, what would we change in the next one, and why?
How many embryos might be frozen from this cycle, and how do they fit into a longer plan?
At what point would you suggest reconsidering the approach, such as different treatment, donor gametes or stopping?
Key takeaways
Cumulative outcomes after several IVF cycles are higher than the result of any single cycle, but the gain from each additional cycle shrinks, and the pattern depends heavily on age and diagnosis. Guidelines on funded cycles are not predictions of what any individual needs. A good plan is built around your own results, reviewed after each cycle, and discussed openly, including the possibility that other routes may be more appropriate than another repeat of the same treatment.
References
- Fertility problems: assessment and treatment (NG257), access criteria for in vitro fertilisation. National Institute for Health and Care Excellence, 2026. https://www.nice.org.uk/guidance/NG257/chapter/access-criteria-for-in-vitro-fertilisation-ivf
- Fertility treatment 2024: trends and figures. Human Fertilisation and Embryology Authority, 2026. https://www.hfea.gov.uk/about-us/publications/research-and-data/fertility-treatment-2024-trends-and-figures
- Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles. JAMA, 2015;314(24):2654-2662. https://pubmed.ncbi.nlm.nih.gov/26717030/
- McLernon DJ, Maheshwari A, Lee AJ, Bhattacharya S. Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women. Human Reproduction, 2016;31(3):572-581. https://abdn.elsevierpure.com/en/publications/cumulative-live-birth-rates-after-one-or-more-complete-cycles-of-/
- Testing and interpreting measures of ovarian reserve: a committee opinion. American Society for Reproductive Medicine, 2020. https://asrm.org/practice-guidance/practice-committee-documents/testing-and-interpreting-measures-of-ovarian-reserve-a-committee-opinion-2020
- The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. American Society for Reproductive Medicine, 2024. https://www.asrm.org/practice-guidance/practice-committee-documents/the-use-of-preimplantation-genetic-testing-for-aneuploidy-a-